Novartis' Maalox Total Relief Rebranding Reflects FDA AER Evolution
This article was originally published in The Tan Sheet
Executive Summary
FDA's request that Novartis rebrand a Maalox line extension is the latest illustration of the agency taking action based on a relatively small number of serious adverse event reports